



NEW DEAL

NEW NANOTHERAPY FOR INFLAMMATORY BOWEL DISEASES

4 YEARS

11 PARTNERS

5 COUNTRIES

6 M€ FUNDING

3 MILLION PEOPLE WITH IBDs IN EUROPE

Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people.

"The NEW DEAL concept could revolutionise IBD therapies for the great benefit of patients and European healthcare systems."


Fabrice NAVARRO, CEA
Coordinator of the New Deal project

THE NEW DEAL CONCEPT

A highly selective and local therapy with an improved efficacy and safety profile for IBD patients.



Nanolipid carrier (NLC) siRNAs. It crosses the intestinal barriers to reach its targets



Microcapsule polymer based Protects and carries the NLCs until it reaches the colon




RNA
RNA molecule



siRNA
Small interfering RNA


TISSUE TARGETING

Oral administration of the capsule




CELLULAR TARGETING

Transit of capsule along the gut intestine tract




MOLECULAR TARGETING

siRNA for JAK3 targeting with high selectivity



THE PROJECT MILESTONES



WANT TO KNOW MORE?

www.newdeal-project.eu

@NewDealEU



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 720905